- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Diatide's AcuTect gets priority review
Peptide-based radiopharmaceutical developer Diatide reported last week that the Food and Drug Administration has accepted the company's new drug application (NDA) filing for AcuTect, and has placed the NDA under priority review status. The FDA reserves
Peptide-based radiopharmaceutical developer Diatide reported last week that the Food and Drug Administration has accepted the company's new drug application (NDA) filing for AcuTect, and has placed the NDA under priority review status. The FDA reserves priority review for products that could be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious or life-threatening disease, according to Londonderry, NH-based Diatide. Receipt of the status means that the review time for AcuTect will most likely be cut in half, with the FDA completing its review in six months. AcuTect is designed for the detection of acute venous thrombosis (SCAN 9/3/97).
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
